About Heterochromatin-stabilizing protein CFDP1
Heterochromatin-stabilizing protein CFDP1 (CFDP1) is a protein
from Homo sapiens identified by UniProt accession
Q9UEE9, 299 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Heterochromatin-stabilizing protein CFDP1 |
|---|
| UniProt accession | Q9UEE9 |
|---|
| Gene | CFDP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 299 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (81)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- systolic blood pressure · score 0.34
- platelet count · score 0.31
- pulse pressure measurement · score 0.31
- FEV/FVC ratio · score 0.31
- diastolic blood pressure · score 0.30
- chronic obstructive pulmonary disease · score 0.29
- coronary artery disease · score 0.29
- smoking status measurement · score 0.27
- migraine disorder · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UEE9-F1 | alphafold | PREDICTED | 63.79 | — |
Amino-acid sequence (299 residues)
MEEFDSEDFS TSEEDEDYVP SGGEYSEDDV NELVKEDEVD GEEQTQKTQG KKRKAQSIPA RKRRQGGLSL EEEEEEDANS ESEGSSSEEE DDAAEQEKGI GSEDARKKKE DELWASFLND VGPKSKVPPS TQVKKGEETE ETSSSKLLVK AEELEKPKET EKVKITKVFD FAGEEVRVTK EVDATSKEAK SFFKQNEKEK PQANVPSALP SLPAGSGLKR SSGMSSLLGK IGAKKQKMST LEKSKLDWES FKEEEGIGEE LAIHNRGKEG YIERKAFLDR VDHRQFEIER DLRLSKMKP
Explore Heterochromatin-stabilizing protein CFDP1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets